No Data
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
Monkeypox epidemic is fermenting! Biomedical stocks on the Hong Kong stock market continue to be active. Institutions are expected to see a concentrated bullish catalyst.
Which mid-term bullish trends are worth paying attention to in the continuously active Hong Kong biomedical sector? What are the highlights of the Wande Innovative Drugs Index outperforming the market since July?
BeiGene Announces New Stock Incentives
Innovative drug concepts are generally rising, Beigene (06160) rose 3.14%. Institutions pointed out that overseas authorization and heavy innovation will be the catalyst for industry investment.
Innovative drug concept rose, Remegen (09995) rose by 4.14%, Beigene (06160) rose by 3.14%, Akeso (09926) rose by 1.84%, Innovent bio (01801) rose by 1.82%, Hutchmed (china) (00013) rose by 1.82%, Frontage (01521) rose by 1.35%, Canbridge Life Sciences-B (02162) rose by 0.63%, Innocare (09969) rose by 0.45%. Sinolink Securities indicated that the performance of the innovative drug companies has shown a clear trend of improvement based on the disclosed interim reports. Beigene and Hutchmed (china) pharmaceutical both performed well.
Party Time: Brokers Just Made Major Increases To Their BeiGene, Ltd. (NASDAQ:BGNE) Earnings Forecasts
No Data
